Ocuphire Pharma Files 8-K for Disclosure and Exhibits

Ticker: IRD · Form: 8-K · Filed: Mar 27, 2024 · CIK: 1228627

Sentiment: neutral

Topics: disclosure, filing, exhibits

Related Tickers: OCUP

TL;DR

OCUP filed an 8-K for routine disclosures, no major news.

AI Summary

Ocuphire Pharma, Inc. filed an 8-K on March 27, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements for these sections.

Why It Matters

This filing indicates standard corporate reporting and does not introduce new material information that would immediately impact the company's stock.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for disclosures and exhibits, not indicating any new risks or material events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and Financial Statements and Exhibits.

What is the date of the earliest event reported in this filing?

The date of the earliest event reported in this filing is March 27, 2024.

In which state was Ocuphire Pharma, Inc. incorporated?

Ocuphire Pharma, Inc. was incorporated in Delaware.

What is the address of Ocuphire Pharma, Inc.'s principal executive offices?

The address of Ocuphire Pharma, Inc.'s principal executive offices is 37000 Grand River Avenue, Suite 120, Farmington Hills, MI 48335.

Does this filing announce any new material events or financial results?

This filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits, and does not appear to announce any new material events or specific financial results beyond standard reporting.

Filing Stats: 500 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-03-27 16:26:21

Key Financial Figures

Filing Documents

01

Item 7.01 Regulation FD Disclosure Representatives of Ocuphire Pharma, Inc. (the " Company ") plan to share the Investor Presentation attached hereto as Exhibit 99.1 in upcoming meetings with investors and others. The information in this Item 7.01 of this Current Report on Form 8-K, and Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. Exhibit No. Description 99.1 Investor Presentation March 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 27, 2024 OCUPHIRE PHARMA, INC. By: /s/ Dr. George Magrath Name: Dr. George Magrath Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing